Associate Professor, Medicine, Case Western Reserve University School of Medicine
Radiation Oncology
Dr. Jay P. Ciezki, MD
|
|
Give Review
Ciezki is an expert in the field of Radiation Oncology. He studied medicine at Medical College of Wisconsin. Medical College of Wisconsin is ranked 54/62 in Research/PrimaryCare. He over the years received 3 awards: "America's Top Doctors", "America's Top Doctors for Cancer" and "CMS Meaningful Use Stage 1 Certification". Ciezki is a published doctor as well. He has 63 publications published. The latest was: Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer. He is registered with Medicare.
Publications
- A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.
- Are Biochemical Recurrence Outcomes Similar After Radical Prostatectomy and Radiation Therapy? Analysis of Prostate Cancer-Specific Mortality by Nomogram-predicted Ris...
- Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
- In reply to jones and menon.
- High-risk prostate cancer in the modern era: does a single standard of care exist?
- Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
- Multi-institutional Prospective Evaluation of Bowel Quality of Life After Prostate External Beam Radiation Therapy Identifies Patient and Treatment Factors Associated ...
- Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity.
- ACR Appropriateness Criteria® external-beam radiation therapy treatment planning for clinically localized prostate cancer.
- ACR Appropriateness Criteria® definitive external beam irradiation in stage T1 and T2 prostate cancer.
- Redefining High-risk Prostate Cancer Based on Distant Metastases and Mortality After High-dose Radiotherapy with Androgen Deprivation Therapy.
- ACR appropriateness criteria postradical prostatectomy irradiation in prostate cancer.
- Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed imp...
- PSA bounce and biochemical failure after brachytherapy for prostate cancer: a study of 820 patients with a minimum of 3 years of follow-up.
- Association of body mass index with prostate cancer biochemical failure.
- The current status of image-guided external beam radiotherapy for prostate cancer.
- Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic vari...
- The importance of serum prostate-specific antigen testing frequency in assessing biochemical and clinical failure after prostate cancer treatment.
- Brachytherapy or surgery? A composite view.
- Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer.
- Brachytherapy for localized prostate cancer.
- Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated...
- Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.
- Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
- Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for localized adenocarcinoma of prostate.
- Comparison of biochemical failure definitions for permanent prostate brachytherapy.
- Aggressiveness of familial prostate cancer.
- Perineural invasion on prostate needle biopsy does not predict biochemical failure following brachytherapy for prostate cancer.
- PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
- Prostate brachytherapy for localized prostate cancer.
- Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomize...
- A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external be...
- Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiothe...
- PSA bounce predicts early success in patients with permanent iodine-125 prostate implant.
- Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy.
- Late toxicity after intensity modulated and image guided radiation therapy for localized prostate cancer and post-prostatectomy patients.
- PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells.
- Carotid brachytherapy for in-stent restenosis.
- Accelerated hyperfractionated radiation, concurrent paclitaxel/cisplatin chemotherapy and surgery for stage III non-small cell lung cancer.
- Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society.
- Fluoroscopic study of tumor motion due to breathing: facilitating precise radiation therapy for lung cancer patients.
- Dosimetric comparison of pre-planned and or-planned prostate seed brachytherapy.
- Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy.
- Dosimetry of a W-188/Re-188 beta line source for endovascular brachytherapy.
- Palliative radiotherapy.
- Cost comparison of radical prostatectomy and transperineal brachytherapy for localized prostate cancer.
- Parenchymal cell proliferation in coronary arteries after percutaneous transluminal coronary angioplasty: a human tissue bank study.
- Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer.
- The palliative role of radiotherapy in the management of the cancer patient.
- Quality of life and satisfaction with outcome among prostate-cancer survivors.
- Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer.
- Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate.
- Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation.
- Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon.
- Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy?
- Early intervention with phosphodiesterase-5 inhibitors after prostate brachytherapy improves subsequent erectile function.
- American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer.
- Low-dose-rate brachytherapy as salvage treatment of local prostate cancer recurrence after radical prostatectomy.
- Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels.
- Prediction of erectile function following treatment for prostate cancer.
- American College of Radiology Appropriateness Criteria(®)--locally advanced (high-risk) prostate cancer.
- High-Dose-Rate Monotherapy for Localized Prostate Cancer-What More Will It Take to Make This a Standard Therapy?
Schools
Medical College of Wisconsin
Cleveland Clinic
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
Education
-
Cleveland Clinic Foundation -
Medical College of Wisconsin
Hospital
-
Cleveland Clinic
Drug Facts
| NPI NUMBER | 1841254588 | |
| NPPES Provider LastName | CIEZKI | |
| NPPES Provider FirstName | JAY | |
| NPPES Provider ZIPCode | 441950001 | |
| NPPES Provider State | OH | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 240.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1841254588 |
| Last Name Of The Provider | CIEZKI |
| First Name Of The Provider | JAY |
| View All |
Similar Doctors
|
|
Dr. Douglas B. Einstein, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suzan S. Cheng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carmen Vermont, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan Guo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John H. Suh, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Anthony Mastroianni, MD |
|
|
Dr. Yvonne T. Pham, MD |
|
|
Dr. Bryan J. Traughber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Aleck A. Hercbergs, MB CHB |
|
|
Dr. Richard H. Matthews, MD |